Natera stock spikes as strong oncology demand drives record test volumes and a full-year revenue outlook bump.

Cancer test name Natera stock is in a buy zone above a cup base ahead of second-quarter results due Thursday.

Natera shares rocketed Friday as the company reported a strong revenue beat.